QUOTE AND NEWS
Market Intelligence Center  Oct 15  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on NPS Pharmaceuticals Inc (NPSP) could yield about 5.82% (22.60% annualized, for comparison purposes only) in 94 days. Pair a long position in the stock with the Jan....
Market Intelligence Center  Oct 9  Comment 
NPS Pharmaceuticals Inc (NPSP) presents a trading opportunity that offers a 14.50% return in just 218 days. A covered call on NPS Pharmaceuticals at the $24.00 level expiring on May. '15 offers an assigned return rate of 14.50% or 24.28%...
Motley Fool  Oct 7  Comment 
NPS Pharmaceuticals' stock is up nearly 150% over the trailing two-year period, yet it's still considered a cheap stock by Wall Street's standards. Find out why Wall Street is so in love with this company and whether its share price can head even...
StreetInsider.com  Sep 24  Comment 
The following is a list of notable articles to help get you through the lunch hour: NPS Pharmaceuticals (NPSP) Gains on Bullish Notes on Natpara Approval -> Read this! CyberArk Software (CYBR) IPO Opens Up 56% -> Read this! Pfizer (PFE) Looks...
Market Intelligence Center  Sep 17  Comment 
NPS Pharmaceuticals Inc (NPSP) presents a trading opportunity that offers a 5.54% return in just 122 days. A covered call on NPS Pharmaceuticals at the $24.00 level expiring on Jan. '15 offers an assigned return rate of 5.54% or 16.58%...
TheStreet.com  Sep 16  Comment 
BALTIMORE (Stockpickr) --aPut down the 10-K filings and the stock screeners. It's time to take a break from the traditional methods of generating investment ideas. Instead, let the crowd do it for you. Read More: 5 Breakout Stocks Under $10 Set...
Trading with the Average Jay  Sep 16  Comment 
This mornings trades are based on the 30minute chart opening High and low breakouts. First trade Long eBay ( EBAY ) based on buying the low with a close stop. Loss   This is what happens when the light comes on and you follow your plans....
Motley Fool  Sep 15  Comment 
NPS Pharmaceuticals' stock is among today's top losers after announcing the results of the FDA panel's vote on whether or not to recommend approval for experimental hypoparathyroidism drug Natpara. Find out what this news means for NPS' shareholders.
Benzinga  Sep 15  Comment 
Net Element (NASDAQ: NETE) declined 24.89% to $4.28. Net Element has eliminated $15 million of debt from its balance sheet. NPS Pharmaceuticals (NASDAQ: NPSP) shares dipped 12.26% to $28.69. The FDA has voted 8-5 in favor of NPS Pharmaceuticals'...
StreetInsider.com  Sep 15  Comment 
Avanir Pharmaceuticals (Nasdaq: AVNR) 47.7% HIGHER ; announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. Treatment with...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki